One-year results for STELARA in Crohn’s disease – The head-to-head SEAVUE Study
Returning guest, Dr. Andrew Greenspan, Vice President of Immunology Medical Affairs at Janssen discusses recent data from the Phase 3b SEAVUE study, the first head-to-head study of biologic therapies in patients with Crohn’s disease, evaluating the safety and efficacy of STELARA® (ustekinumab) compared with adalimumab through one year of treatment in biologic-naïve patients. These data were presented at this year’s Digestive Disease Week (DDW) Virtual 2021, where Janssen Immunology presented 20 abstracts in total from the company’s gastroenterology portfolio and pipeline.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Arthritis. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Arthritis and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Arthritis?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
As Vice President of Immunology Medical Affairs, Andrew Greenspan, M.D., is responsible for leadership and oversight of Immunology Medical Affairs activities supporting REMICADE® (infliximab), SIMPONI® (golimumab), SIMPONI ARIA® (golimumab for infusion), STELARA® (ustekinumab) and TREMFYA® (guselkumab) for a wide range of diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis.
Listen on Soundcloud.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
